ClinicalTrials HQ

Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A

Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A

Recruiting · NCT05500807 · Registry updated 2026-04-03
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia ACongenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder, von Willebrand disease (hereditary or acquired), von Willebrand disease 3RecruitingPhase 12026-04-03NCT05500807

2 results · Page 1 of 1

Organizations

Swipe the table sideways for more columns.

OrganizationsLinked trials
Bleeding and Clotting Disorders Institute Peoria, Illinois1
Genentech, Inc.221

12 results · Page 1 of 1

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Bleeding and Clotting Disorders Institute (BCDI)PeoriaUnited States1
Central Michigan University: Children's Hospital of MichiganMount PleasantUnited States1
Children's Mercy HospitalKansas CityUnited States54
Innovative Hematology, Inc. (IHI)IndianapolisUnited States1
Penn State College of MedicineHersheyUnited States17
St. Joseph's Children's Hospital - Center for Bleeding and Clotting DisordersTampaUnited States1
Stanford University: Stanford Children's HealthRedwood CityUnited States1
The Center for Comprehensive Care and Diagnosis of Inherited Blood Disorders (CIBD)OrangeUnited States1
University of Miami - Miller School of MedicineCoral GablesUnited States1
University of Michigan Medical SchoolAnn ArborUnited States4
UW Health Comprehensive Program for Bleeding DisordersMadisonUnited States1
Washington Center for Bleeding DisordersSeattleUnited States5